Timeisbrain is a Spain-based MedTech startup that developed the BraiN20, a medical device designed to address the best management of Acute Ischemic Stroke. The company's slogan, "Our medical device BraiN20 adresses the best management of Acute Ischemic Stroke," encapsulates their mission to combat the devastating effects of stroke. With 15 million people worldwide suffering from stroke annually, Timeisbrain aims to revolutionize the treatment of Acute Ischemic Stroke (AIS) with their innovative solution, BraiN20.
The BraiN20 boasts unique features, including a novel portable medical device and a stroke ECG. Moreover, the company's proprietary algorithm, based on extensive research in real patients, sets it apart. Their tailored design and development, adjusted to end-users' requirements, demonstrate a commitment to efficacy and user satisfaction.
The recent Pre Seed Round investment in December 2022 from The European Innovation Council underscores investor confidence in Timeisbrain's potential. This financial backing will likely fuel the company's efforts to increase patient candidates for Endovascular Treatment, reduce time-to-treatment, and improve the outcome of EVT. With a strong Board of Directors comprising accomplished individuals, including Alicia Martínez and Antoni Dávalos, the company is backed by a wealth of expertise and experience.
Timeisbrain's innovative approach and strategic investments position it as a promising player in the healthcare industry, with the potential to make a significant impact on stroke management and patient outcomes.
No recent news or press coverage available for Time is Brain.